16 results on '"Ohba, Shigeo"'
Search Results
2. TMET-18. TARGETING AMINO ACID METABOLIC VULNERABILITIES IN GLIOBLASTOMA
3. TAMI-56. TARGETING AMINO ACID METABOLIC VULNERABILITIES IN IDH-MUTANT AND IDH-WILDTYPE GLIOMAS
4. MODL-15. THE COMBINATION TREATMENT OF PARP INHIBITOR AND TMZ, OR DAG WILL BE PROMISING TREATMENT IN SF8628
5. CSIG-19. THE DEUBIQUITINASE BRCC3 LINKS ALT TELOMERES TO SUPPRESSION OF INNATE IMMUNITY IN IDH1-MUTANT GLIOMA
6. DDRE-15. THE COMBINATION THERAPY OF PARP INHIBITOR AND TMZ IN DIFFUSE MIDLINE GLIOMA HARBORING H3 K27M-MUTANT
7. CBMT-19. THE ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM PROVIDES COLLATERAL SENSITIVITY TO LETHAL TELOMERIC FUSION INDUCED BY TRAPPING PARP INHIBITORS
8. DRES-03. PARP INHIBITOR, INHIBITION OF HOMOLOGOUS RECOMBINATION, OR DIANHYDRODULCITOL CAN OVERCOME TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
9. DRES-19. THE MECHANISMS OF RESISTANCE TO TEMOZOLOMIDE IN GLIOMA CELLS
10. CSIG-40. PHOSPHOGLYCERATE MUTASE 1 (PGAM1) ACTIVATES DNA DAMAGE REPAIR VIA REGULATION OF WIP1 ACTIVITY
11. CSIG-08. MUTANT IDH1 CO-OPERATES WITH ATRX LOSS TO DRIVE THE ALTERNATIVE LENGTHENING OF TELOMERE (ALT) PHENOTYPE IN GLIOMA
12. DRES-03. INHIBITION OF HOMOLOGOUS RECOMBINATION RESENSITIZES TEMOZOLOMIDE-RESISTANT GLIOMA CELLS TO TEMOZOLOMIDE
13. EXTH-47. RAPID CONVERSION OF MUTANT IDH1 FROM DRIVER TO PASSENGER IN A MODEL OF HUMAN GLIOMAGENESIS
14. CBIO-02. MUTANT IDH EXPRESSION DRIVES TERT PROMOTER REACTIVATION AS PART OF THE CELLULAR TRANSFORMATION PROCESS
15. CBIO-32MUTANT IDH EXPRESSION DRIVES hTERT REACTIVATION AS PART OF THE CELLULAR TRANSFORMATION PROCESS
16. MUTANT IDH1-DRIVEN CELLULAR TRANSFORMATION INCREASES RAD51-MEDIATED HOMOLOGOUS RECOMBINATION AND TEMOZOLOMIDE (TMZ) RESISTANCE.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.